Chi Meng Fong
Stock Analyst at Bank of America Securities
(1.31)
# 3,695
Out of 5,088 analysts
51
Total ratings
41.7%
Success rate
-2.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chi Meng Fong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Maintained: Buy | n/a | $41.84 | - | 4 | Oct 30, 2026 | |
| RLAY Relay Therapeutics | Reiterated: Buy | $25 | $19.47 | +28.40% | 7 | Oct 23, 2026 | |
| ROIV Roivant Sciences | Reiterated: Hold | $41 | $37.52 | +9.28% | 30 | Oct 21, 2026 | |
| CCCC C4 Therapeutics | Rated: Hold | n/a | $3.30 | n/a | 5 | Oct 31, 2023 | |
| FHTX Foghorn Therapeutics | Rated: Hold | n/a | $2.09 | n/a | 5 | Oct 6, 2023 |
Supernus Pharmaceuticals
Oct 30, 2026
Maintained: Buy
Price Target: n/a
Current: $41.84
Upside: -
Relay Therapeutics
Oct 23, 2026
Reiterated: Buy
Price Target: $25
Current: $19.47
Upside: +28.40%
Roivant Sciences
Oct 21, 2026
Reiterated: Hold
Price Target: $41
Current: $37.52
Upside: +9.28%
C4 Therapeutics
Oct 31, 2023
Rated: Hold
Price Target: n/a
Current: $3.30
Upside: n/a
Foghorn Therapeutics
Oct 6, 2023
Rated: Hold
Price Target: n/a
Current: $2.09
Upside: n/a